LA JOLLA, Calif.--(BUSINESS WIRE)--InflammaGen Therapeutics (a portfolio Company of Leading Biosciences) will be presenting at Boston’s BioPharm America Meeting, September 9, 2011. In collaboration with the Bioengineering Department at the University of California, San Diego (UCSD), InflammaGen Therapeutics has developed a new diagnostic assay and therapy to help clinicians diagnose, prevent and/or treat multi-organ failure as a result of acute shock (septic, hemorrhagic, cardiogenic, etc.).
